(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 February 2012 (02.02.2012)

PCT

(10) International Publication Number
WO 2012/013609 A1

(51) **International Patent Classification**:
C07K 16/26 (2006.01)

(21) **International Application Number**:
PCT/EP2011/062686

(22) **International Filing Date**:
22 July 2011 (22.07.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

61/367,851	26 July 2010 (26.07.2010)	US
61/476,204	15 April 2011 (15.04.2011)	US

(71) **Applicants** *(for all designated States except US)*: **BIORÉALITÉS S.A.S.** [FR/FR]; 2040 Avenue du Pere Soulas, F-34000 Montpellier (FR). **INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)** [FR/FR]; 101 Rue de Tolbiac, Cedex 13, F-75654 Paris (FR). **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)** [FR/FR]; Campus Gerard-Megie, 3 rue Michel-Ange, Cedex 16, F-75794 Paris (FR).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **HOUHOU, Leila** [FR/FR]; 2 rue Renaud de Villeneuve, F-34090 Montpellier (FR). **DUMÉ, Anne-Sophie** [FR/FR]; 76 Rue de St. Priest, F-34090 Montpellier (FR). **JOUBERT, Dominique** [FR/FR]; 10 rue Gabriel Peri, F-34200 Sete (FR). **HOLLANDE, Frederic** [FR/FR]; 63 chemin de la Deridiere, F-34270 Les Matelles (FR).

(74) **Agent**: **ROQUES, Sarah, E.**; J A Kemp & Co, 14 South Square, Gray's Inn, London Greater London WC1R 5JJ (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2012/013609 A1

(54) **Title**: METHODS AND COMPOSITIONS FOR LIVER CANCER THERAPY

(57) **Abstract**: The present disclosure provides methods of treating liver cancer and preventing liver cancer recurrence with anti-progastrin antibodies, methods of monitoring treatment efficacy of anti-progastrin therapy for liver cancer, and compositions useful therefore.